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type 9 inhibitor, signiﬁcantly reduces low-density lipoprotein choles-
terol, but requires subcutaneous injections rather than oral pills. To
measure patients’ acceptance of this treatment modality, a new
patient-reported outcome, the Injection-Treatment Acceptance Ques-
tionnaire (I-TAQ), was developed. Objectives: To psychometrically
evaluate the I-TAQ with patients at high risk of cardiovascular events
receiving alirocumab. Methods: The 22-item, 5-domain I-TAQ was
administered cross-sectionally to 151 patients enrolled in alirocumab
clinical trials. Item response distributions, factor and multitrait
analyses, interitem correlations, correlations with an existing meas-
ure of acceptance (convergent validity), and comparison of known-
groups were performed to assess the I-TAQ’s psychometric properties.
Results: Completion rates were high, with no patients missing more
than two items and 91.4% missing no data. All items displayed high
ceiling effects (430%) because of high treatment acceptance. Factor
analysis supported the a priori hypothesized item-domain structure
with good ﬁt indices (root mean square error approximation ¼ 0.070;
comparative ﬁt index ¼ 0.988) and high factor loadings. All itemsee front matter Copyright & 2016, International S
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ndence to: Sophi Tatlock, Adelphi Values Ltd., Adedemonstrated item convergent validity (item-scale correlationZ0.40),
except for the side effects domain, which was limited by small
numbers (n ¼ 46). Almost all items correlated most highly with the
domain to which they were assigned (item discriminant validity).
Internal reliability was acceptable for all domains (Cronbach α range
0.72–0.88) and convergent validity was supported by a logical pattern
of correlations with the Chronic Treatment Acceptance Question-
naire. Conclusions: These ﬁndings provide initial evidence of validity
and reliability for the I-TAQ in patients treated with subcutaneous
alirocumab. The I-TAQ could prove to be a valuable patient-reported
outcome for therapies requiring subcutaneous injection.
Keywords: acceptance, instrument development, patient-reported
outcome, qualitative research.
Copyright & 2016, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Elevated low-density lipoprotein cholesterol (LDL-C) levels are
associated with an increased risk of cardiovascular (CV) events [1],
occurring in more than 2 million Americans each year and
accounting for approximately one-quarter of total inpatient costs
[2]. Lowering LDL-C levels with statin and nonstatin lipid-modifying
therapies [3] reduces the risk of CV events [4]. Alirocumab is a fully
human monoclonal antibody against proprotein convertase sub-
tilisin/kexin type 9 that is administered via subcutaneous injection
for the treatment of elevated LDL-C levels. Alirocumab has demon-
strated signiﬁcant incremental reduction in LDL-C levels with or
without background statin therapy [5–9].Given the requirement for subcutaneous, as opposed to oral,
administration, there is a need to assess patients’ acceptance of
the subcutaneous treatment approach. Accordingly, a novel
patient-reported outcome (PRO) instrument, the Injection-
Treatment Acceptance Questionnaire (I-TAQ), was developed to
measure treatment acceptance. The concepts generated from a
literature and instrument review informed the initial drafting of a
17-item version of the I-TAQ. Content validity, as outlined in the
Food and Drug Administration PRO guidance [10], was then
assessed through three successive rounds of qualitative inter-
views conducted with 29 US-English–speaking patients who were
participating in the phase III program for alirocumab. Each round
of interviews included both concept elicitation (to ensure noociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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debrieﬁng activities (to provide further evidence of relevance
and ensure the items were well understood), the results of which
informed revisions to the measure, resulting in a 22-item I-TAQ
with established content validity [11].
Once the content validity of the I-TAQ was established, an
evaluation of the instrument’s psychometric properties was
required to evaluate reliability and validity in measuring patients’
acceptance of subcutaneous treatments. The primary objective of
this study, therefore, was to evaluate the psychometric properties
of the I-TAQ to ﬁnalize the conceptual framework, evaluate the
appropriateness of the a priori hypothesized scoring algorithm,
and establish its validity and reliability.Methods
Study Design
This was a multicenter, non-interventional, cross-sectional study
to psychometrically validate the I-TAQ. The 22-item I-TAQ as
well as two other PROs used for convergent validity, the Chronic
Treatment Acceptance Questionnaire (ACCEPT) and a patient
global impression of acceptance (PGI-A) measure, were all admin-
istered at one time point to each participant. The analyses are
presented in Figure 1. The appropriateness of the a priori con-
ceptual framework and the scoring algorithm were evaluated
through the examination of item-level statistics and dimension-
ality analyses. Then, the resulting measure and the scoringFig. 1 – Overview of salgorithm were subject to psychometric validation to evaluate
the validity and reliability of the established scores.
The study was conducted in accordance with the Declaration
of Helsinki and was overseen by a centralized independent
review board in the United States (ethical approval reference:
ADE1-14-383). Written informed consent was obtained from all
participants before the collection of any data and before any
study-related activities.
Patient Recruitment
All 151 patients were enrolled in alirocumab phase III trials and
were recruited for participation in this observational study
through 11 clinical sites in the United States. All patients were
diagnosed with elevated LDL-C levels and were 18 years or older.
The inclusion criteria required all patients to have experience of
self-administering alirocumab (or placebo) via preﬁlled pen or
preﬁlled syringe. Patients self-injecting alirocumab (or placebo),
either as a single 1-ml dose every 2 weeks or two 1-ml doses
every 4 weeks, were considered eligible for the study.
Data Collection
PRO measures
Injection-Treatment Acceptance Questionnaire. The I-TAQ is a
22-item, self-administered questionnaire, developed as a meas-
ure of treatment acceptance in patients who inject their medi-
cations via subcutaneous injections (Appendix A). The I-TAQ
assesses ﬁve domains of treatment acceptance: perceivedtudy analyses.
V A L U E I N H E A L T H ] ( 2 0 1 6 ) ] ] ] – ] ] ] 3efﬁcacy (items 1 and 2, the patient’s perception of whether their
treatment is working), acceptance of side effects (items 3–7, 11,
and 12), injection self-efﬁcacy (items 8–10, the ability of the
patient to perform the task asked of them, e.g., self-injection),
injection convenience (items 13–19), and overall acceptance
(items 20–22). All items have a 4-week recall period and are
answered on a 5-point verbal descriptor scale, with the exception
of items 3 (side effects) and 11 (pain), which use “yes/no”
dichotomous response options. Items 3 and 11 are gateway items
that allow patients to skip non-relevant items associated with
side effects or pain.
Chronic Treatment Acceptance Questionnaire. The ACCEPT is a
32-item, self-administered questionnaire designed to assess
long-term acceptance of a wide range of long-term medications.
The items are organized into six domains: drug characteristics
(items 1–5), duration (items 6 and 7), constraints (items 8–18), side
effects (items 19–24), efﬁcacy (items 25–28), and global acceptance
(items 29–32). A recall period is not speciﬁed. With the exception
of the four-item global acceptance domain, all items are
answered on a 3-point adjectival response scale, and when
relevant, a “not applicable” response option is included. The four
items in the global acceptance domain employ a 5-point adjec-
tival response scale.
PGI-A measure. A PGI-A was created for this study, comprising a
single item asking patients to rate their total experience of using
the study treatment on a 10-point scale, ranging from “very
unacceptable” (1) to “very acceptable” (10).
Statistical Analyses
All items in the I-TAQ were scored from 0 to 4, with 0 indicating
low acceptance and 4 indicating high acceptance. Three items
measuring interference of side effects were reverse-scored to
ensure that the direction of scoring was consistent for all
analyses.
Item-level and dimensionality analyses
Item-level and dimensionality analyses (Fig. 1) were conducted to
evaluate the appropriateness of the a priori conceptual framework
and the hypothesized scoring algorithm for the I-TAQ.
Level of missing data. Missing data levels were assessed and any
item with a substantial amount of missing data (deﬁned a priori
as 430%) was considered for deletion.
Item response distributions. Item response distributions and
ﬂoor and ceiling effects were examined for each item, including
whether any item met the criteria for maximum endorsement
frequencies (480% of responses in a particular category) or
aggregate adjacent endorsement frequencies (two or more adja-
cent response categories on an item showing o10% of
responses). Items with any overly favored response options or
substantial ﬂoor or ceiling effects (420% of patients selecting the
best or worst possible response for an item) were ﬂagged for
further consideration.
Use of skip patterns. Data from patients who incorrectly fol-
lowed the skip patterns (i.e., answered the items they should
have skipped according to their response to the gateway item)
were analyzed separately, in addition to the total sample.
Inter-item correlations and factor analysis. Inter-item correla-
tions were assessed and items with particularly high inter-itemcorrelations (40.80) were considered in terms of potential redun-
dancy. Conﬁrmatory factor analysis (CFA) was conducted to
evaluate the ﬁt with the hypothesized ﬁve-domain framework
(perceived efﬁcacy, acceptance of side effects, injection self-
efﬁcacy, injection convenience, and overall acceptance). Model
ﬁt was assessed by calculating the comparative ﬁt index (CFI;
40.95 for evidence of good ﬁt [12]), root mean square error
approximation (RMSEA; o0.08 for acceptable ﬁt [12]), and mod-
iﬁcation indices. The weighted least squares with mean and
variance adjustment (WLSMV) method of estimation was used
to analyze polychoric correlations. Although there was an a priori
hypothesized conceptual framework, exploratory factor analysis
(EFA) was also performed to evaluate whether any alternative
item-domain grouping might emerge. Crawford-Ferguson (CF)
quartimax (equivalent to direct quartimin in oblique rotation)
was used for the rotation method in the EFA. For both CFA and
EFA, items with standardized coefﬁcients of less than 0.30 would
be ﬂagged as candidates for possible deletion. It is also note-
worthy that the WLSMV method of estimation used for EFA and
CFA models employed a “pairwise present” approach to missing-
ness where “limited information” from pairs of variables (item-
pairs) was used. The analyses were conducted using MPlus
(Muthén & Muthén, Los Angeles, CA), which used all individuals
with observations on that item-pair to derive the point estimates.
Thus, all available observations were used to estimate each
correlation, that is, the sample size varied for each correlation.
This is important to note in relation to the side effects items,
because those items were effectively missing for patients who did
not experience side effects, resulting in much smaller sample
sizes for the correlations involving those items.
Internal consistency. Internal reliability analyses (Cronbach α
40.70 being considered as a threshold for deﬁning high internal
reliability) were conducted to assess the homogeneity of items
belonging to the same subscale or multi-item domain.
Item reduction process
The psychometric validation results were discussed during a
daylong, face-to-face item reduction meeting that included as
participants all the authors: two health outcomes researchers,
three PRO developers, and an expert clinician who also had
experience of developing PRO instruments. During the item
reduction meeting, the conceptual relevance (informed by pre-
vious qualitative research ﬁndings [11]) and clinical importance
of items were considered alongside the results of the item
response and dimensionality analyses described earlier. As such,
the face and content validity of the items was given equal
consideration as the initial psychometric ﬁndings when consid-
ering item deletion: an item considered important conceptually
was not deleted on the basis of psychometric ﬁndings alone. A
scoring algorithm and recommendations on how to treat missing
data in the calculation of the I-TAQ total score were then deﬁned,
as described in the Results section. Following the development of
the scoring algorithm, the psychometric properties of the result-
ing I-TAQ scores were assessed.
Psychometric evaluation analyses
Construct validity of the ﬁnal measure was evaluated through
assessment of CFA, multitrait analysis, convergent validity
(examining correlations with other existing instruments), and
known-groups analysis.
CFA and EFA. CFA was conducted again to conﬁrm whether the
I-TAQ items ﬁt within the ﬁnal conceptual framework. EFA was
also performed to verify whether any other item-domain
Table 1 – Patient demographic and clinical
characteristics.
Patient characteristic Total
(n ¼ 151)
Age (y)
Mean SD 63.0  10.9
Median 62.0
Minimum to maximum 33.0–89.0
Sex, n (%)
Male 98 (64.9%)
Female 53 (35.1%)
Highest level of education, n (%)
High school diploma or equivalent 52 (34.4%)
Undergraduate or bachelor’s degree 38 (25.2%)
Graduate degree 28 (18.5%)
Other 25 (16.6%)
Some high school education, but no diploma or GED 8 (5.3%)
Work status
Working full-time 71 (47.0%)
Retired 58 (38.4%)
Not working because of medical condition 16 (10.6%)
Unemployed 5 (3.3%)
Other 1 (0.7%)
Ethnicity
Non-Hispanic/non-Latino 147 (97.4%)
Hispanic or Latino (of any race) 3 (2.0%)
Missing 1 (0.7%)
Race
White 121 (80.1%)
Black/African American 24 (15.9%)
Other 6 (4.0%)
Diagnosed with HeFH or any other genetic
LDL-C–related disorder
No 100 (66.2%)
Yes 51 (33.8%)
Level of CV risk
Very high risk of CV events 70 (46.4%)
High risk of CV events 68 (45.0%)
Moderate 12 (7.9%)
Missing 1 (0.7%)
Concomitant or background treatments*
Statin therapy 93 (61.6%)
High-potency statin 84 (55.6%)
Moderate- to low-potency statin 9 (6.0%)
Ezetimibe 25 (16.6%)
Other 5 (3.3%)
Niacin, ﬁbrate, bile acid sequestrant 6 (4.0%)
Missing 42 (28.0%)
How long has the patient been diagnosed with
hypercholesterolemia?
8þ y ago (2005 or earlier) 39 (76.5%)
4–7 y ago (2010–2006) 2 (3.9%)
Within the last 3 y (2011–2014) 10 (19.6%)
Length of time receiving the study injection treatment
12þ mo 66 (43.7%)
7–11 mo 45 (29.8%)
1–6 mo 39 (25.8%)
Missing 1 (0.7%)
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thresholds expected for CFA and EFA were as described in an
earlier section, as was the rotation method used in the EFA.
Multitrait analysis. Multitrait analysis was conducted using
Pearson correlation coefﬁcients to examine item-scale correla-
tions, corrected for overlap (i.e., each item was correlated with its
own scale, but with the item score removed ﬁrst). Two criteria
were considered: item convergent validity (the correlation coef-
ﬁcient between each item and its own domain [with the item
removed] should be at least 0.40 [13,14]) and item discriminant
validity (each item should correlate more highly with its own
domain [with the item removed] than with any other domain
[13,14]).
Convergent validity. Scale-level convergent validity was eval-
uated by examining the correlations of the I-TAQ domain scores
with the scores of the ACCEPT measure. Correlations of more
than 0.40 were expected among domains measuring similar
concepts, and correlations of less than 0.40 were expected among
domains measuring dissimilar concepts. Details of the speciﬁc
domains that were hypothesized to correlate more than 0.40 are
provided in Appendix B.
Known-groups analysis. The known-groups method was used
to evaluate differences in scores among patients who differed on
the following identiﬁed variables: type of diagnosis (e.g., heredi-
tary familial hypercholesterolemia (HeFH) vs. non-HeFH), severity
of CV risk (e.g., high risk vs. very high risk), mode of admin-
istration (e.g., preﬁlled pen vs. preﬁlled syringe), and overall
treatment acceptance on the PGI-A. It was expected that because
HeFH is a genetic condition, those patients may have higher
treatment acceptance of a subcutaneous treatment, and patients
at very high risk of CV events may also have a higher acceptance
because of the increased perceived beneﬁt of treatment. It was
expected that patients who have a high overall acceptance on the
PGI-A would also report high acceptance scores on the I-TAQ and
patients using a preﬁlled pen would report higher acceptance
than those using a preﬁlled syringe. All these analyses, however,
were considered exploratory, because it was not possible to
postulate a priori how closely treatment acceptance would be
related to these parameters. Group comparisons were performed
using t tests under the condition of normal distributions being
validated.
All analyses were performed using SAS version 9.4 (SAS
Institute, Inc., Cary, NC) apart from factor analyses, which were
performed using Mplus version 7.11 (Muthén & Muthén, Los
Angeles, CA), and multitrait analysis, which was performed using
MAP-R for Windows, version 1.0 [13].Treatment administration
Preﬁlled pen 112 (74.2%)
Preﬁlled syringe 36 (23.8%)
Missing 3 (2.0%)
CV, cardiovascular; GED, general educational development; HeFH,
hereditary familial hypercholesterolemia; LDL-C, low-density lipo-
protein cholesterol.
* More than one category could be selected for a given patient.Results
Demographic and Clinical Characteristics
Most of the patients (74.2%) included in the study administered
their treatment using a preﬁlled pen. The mean age was 63  10.9
years and 64.9% (n ¼ 53) were male (Table 1). Approximately a
third of the patients (n ¼ 51; 33.8%) had been diagnosed with
HeFH, three-quarter of whom had been diagnosed for more than
8 years. Just less than half of the patients (n ¼ 70; 46.4%) were
deemed to be at very high risk of CV events, with a similar
proportion at high risk (n ¼ 68; 45%) [15]. More than half of the
patients were taking a high-potency statin in addition to alir-
ocumab (n ¼ 84; 55.6%).Item-Level and Initial Dimensionality Results
Level of missing data
Levels of missing data for the I-TAQ were low with no patients
missing more than two items and 91.4% completing all items.
In addition, no individual items were missed by more than
6.6% (n ¼ 10) of the patients.
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The responses for items were positively skewed, indicating high
levels of acceptance, and all items demonstrated ceiling effects
(420% of patients providing the best possible response). The side
effect items (although completed by only those experiencing side
effects; n ¼ 20 [13%]) displayed the highest ceiling effects (80–90%
scoring at ceiling), meeting the criteria for maximum endorse-
ment frequencies. Several other items also had very high ceiling
effects with more than 50% of the patients choosing the highest
possible response (items 8–10, 13–16, and 18–21). All items had
very few patients scoring at the ﬂoor (Appendix C). In addition,
because of the skewed nature of the data, several items met the
criteria for aggregate adjacent endorsement frequencies.
Use of skip patterns
Of the 131 patients who reported no side effects, 26 (17.2%)
answered “no” to item 3, yet continued to answer items 4 to 7
(i.e., failing to follow the instruction that they should skip those
items). Of the 132 patients who reported no pain, 10 (6.6%)
patients answered “no” to item 11, but answered item 12 (i.e.,
incorrectly responded to the item they were instructed to skip).
Inter-item correlations
Inter-item correlations were examined (Appendix D). Excluding
the side effects items, which were all highly correlated, ﬁve item-
pairs correlated above the a priori threshold (40.80), suggesting
potential redundancy. Nevertheless, when the item content of
each pair was examined alongside the results of the qualitative
content validity study [11], all were considered conceptually
distinct. The side effects items were all highly correlated with
each other (r ¼ 0.84–0.98), most likely in part because of the
ceiling effects and small sample size completing the items (n ¼
20). Although the content of some of the items was closely
related, none of the concepts measured were considered sufﬁ-
ciently redundant in light of the previous qualitative ﬁndings [11]
to support deletion. In addition, the supportive factor analysis
results (described later), the concepts being assessed, and the
skewed data, the inter-item correlations were not considered
sufﬁcient evidence to warrant deletion of any of these items at
this time.
Calculation of Cronbach α for each domain with each item
removed in turn
Calculation of Cronbach α for each domain with each item
removed in turn suggested that only two items, if removed,
would result in a very minor increase in the overall consistency
of the scales. Speciﬁcally, item 12 from the acceptance of side
effects domain (Cronbach α increased from 0.75 to 0.81) and item
10 from the injection self-efﬁcacy domain (Cronbach α increased
from 0.71 to 0.72) were ﬂagged, but as the increase in internal
consistency was very minor, this was not considered an adequate
basis for deletion.
CFA ﬁve-factor results
Results of the CFA supported the hypothesized ﬁve-factor struc-
ture (Appendix E). It is noteworthy that items 3 (“do you have side
effects”) and 11 (“do you have pain”) were not included in the
analysis because they were gateway items, and the side effects
items 5, 6, and 7 were removed due to the small sample size that
completed those items. For the resulting ﬁve-factor solution,
standardized factor loadings demonstrated all items loaded
strongly onto their hypothesized domain (40.70), with 12 items
loading onto their respective domain at 0.80 or higher. Theoverall acceptance domain correlated highly with all other
domains with the exception of side effects (perceived efﬁcacy ¼
0.72; injection self-efﬁcacy ¼ 0.71; injection convenience ¼ 0.83).
Otherwise, correlations among factors were generally small to
moderate, ranging from 0.02 (between perceived efﬁcacy and
acceptance of side effects) and 0.83 (between injection self-
efﬁcacy and injection convenience). Model ﬁt indices demon-
strated acceptable model ﬁt (RMSEA ¼ 0.065; CFI ¼ 0.985). In the
EFA, three factors had eigenvalues higher than 1, but the scree
plot was considered to level out between four and ﬁve factors
(Appendix F). The ﬁve-factor solution provided the best account
of the data and mirrored the a priori conceptual framework, with
all but four items loading onto their respective factor at higher
than 0.70.
Item Reduction and Development of Scoring Algorithm
The CFA and EFA results supported the hypothesized ﬁve-factor
conceptual framework and there were no strong arguments for
item deletion. In addition, a cautious, conservative approach was
taken toward deleting any items because of the skewed response
distributions for most items; these skewed response distributions
were considered reﬂective of very high acceptance in this sample
rather than an inherent limitation of the instrument. Given the
skewed data, it was considered prudent to err on the side of
caution by retaining items at this point, rather than risk deleting
items that may have importance in other study populations.
Deletion of item 15 (“time to give injection”) was considered
given the very high correlation with item 14 (“time taken to
prepare”) (r ¼ 0.91). Nevertheless, the qualitative research during
instrument development supported items 14 and 15 being con-
ceptually distinct, and injections for some treatments may take a
relatively long time to administer, for example, time it takes to
physically inject the medication, which could potentially impact
acceptance separately from the time required to prepare an
injection [11]. In addition, the factor analysis results provide
evidence supporting the item-scale structure of the instrument
with all items retained. Therefore, this item was retained pending
further testing in future studies with more evenly distributed
data to assess the conceptual distinctness of these items.
Although only a small proportion of the sample reported side
effects, it was agreed that it was important to capture any
presence (and resulting impacts) of side effects, and these items
were also retained. Even with all items retained, the instrument
length (22 items) and time required to complete it (approximately
5–10 minutes for most patients) did not suggest problematic
respondent burden. It was also decided that responses from
patients who incorrectly followed the skip pattern (e.g., reported
“no” side effects or pain but continued to answer the items
associated with side effects or pain) should be included in the
calculation of the total score on the basis that if patients have
taken the time to provide an answer, then it should be included
in the data. Nevertheless, because the overall acceptance domain
was highly correlated with all other domains apart from the
acceptance of side effects domain, it was decided to exclude it
from the total score. Therefore, a revised four-factor conceptual
framework (excluding the overall acceptance items and including
patients who had incorrectly followed the skip pattern) was
psychometrically evaluated.
Development of scoring algorithm
Because items in the overall acceptance domain were highly
correlated with all domains except the acceptance of side effects
domain, they were excluded from the scoring algorithm. Domain
scores were then derived as the sum of scores for items answered
V A L U E I N H E A L T H ] ( 2 0 1 6 ) ] ] ] – ] ] ]6divided by the total possible score for items answered multiplied
by 100. The total score was calculated as follows:
ðPerceived efficacy scoreþAcceptance of side effects scoreþ
Injection self-efficacy scoreþ Injection convenience scoreÞ
4:
The scores are based on at least 50% of the items being non-
missing. Figure 2 presents the revised conceptual framework for
the I-TAQ.
Psychometric Evaluation of the Finalized I-TAQ Using Scoring
Algorithm
CFA four-factor results
The CFA and EFA were conducted with a sample of 151 patients
and a WLSMV method of estimation was used. The CFA
supported the construct validity of the revised four-factor
framework (Fig. 3), with all items loading highly onto their
hypothesized factor (40.70). The correlations among factors
were generally small to moderate, ranging from 0.02 (between
perceived efﬁcacy and acceptance of side effects) to 0.716
(between injection self-efﬁcacy and injection convenience).
The CFA had acceptable model ﬁt (indicated by RMSEA ¼ 0.066
and CFI ¼ 0.989). For the EFA, the ﬁrst four factors all had
eigenvalues higher than 1 (range 6.895–1.292; the eigenvalue for
the ﬁfth factor dropped to 0.797) and a four-factor solution
provided the best account of the data (RMSEA ¼ 0.062 andTable 2 – EFA CF-quartimax rotated loadings.
Items
Factor 1 (perceiv
1. Over the past 4 wk, how conﬁdent were you that the injection treatm
condition?
2. Over the past 4 wk, how effective was the injection treatment at trea
Factor 2 (self
8. Over the past 4 wk, how conﬁdent did you feel in your ability to give y
treatment?
9. Over the past 4 wk, how easy or difﬁcult was it to give yourself the in
10. Over the past 4 wk, how acceptable or unacceptable did you ﬁnd giv
injection treatment?
Factor 3 (side
4. Over the past 4 wk, how acceptable or unacceptable did you ﬁnd the
injection treatment?
12. Over the past 4 wk, how acceptable or unacceptable did you ﬁnd the p
when injecting your treatment?
Factor 4 (injection
13. Over the past 4 wk, how acceptable or unacceptable did you ﬁnd the w
the injection treatment?
14. Over the past 4 wk, how acceptable or unacceptable did you ﬁnd the
prepare your injection treatment?
15. Over the past 4 wk, how acceptable or unacceptable did you ﬁnd the
yourself the injection treatment?
16. Over the past 4 wk, how acceptable or unacceptable did you ﬁnd the n
had to give yourself the injection treatment?
17. Over the past 4 wk, how easy or difﬁcult was it to remember to give y
treatment?
18. Over the past 4 wk, how easy or difﬁcult was it to ﬁt in taking the inje
life?
19. Over the past 4 wk, how convenient or inconvenient did you ﬁnd tak
treatment?
EFA, exploratory factor analysis.
* P ¼ 0.05.CFI ¼ 0.995) (Table 2). Encouragingly, all items also loaded
(40.50) on exactly the same factors as in the ﬁnal CFA. All items
loaded most highly on their own factor and did not load at
higher than 0.40 on any other factor.Multitrait analysis
In a multitrait analysis, items in all domains, except the accept-
ance of side effects domain, surpassed the criterion for item
convergent validity (correlations of 40.40 with the item’s own
domain) (Table 3). All items in the acceptance of side effects
domain failed to meet the criterion for item convergent validity,
but the small sample size and highly skewed response distribu-
tions precluded a deﬁnitive assessment of this domain.
All items in all domains, apart from the acceptance of side
effects domain, met the criterion for item discriminant validity
(each item had a higher correlation with the item’s own domain
than any other domain). The following two items did not
demonstrate discriminant validity: item 4 ('acceptance of side
effects'; r ¼ 0.31 vs. r ¼ 0.35 with injection convenience domain)
and item 6 ('side effects interfere with leisure/free time'; r ¼ 0.31
vs. r ¼ 0.44 with self-efﬁcacy domain).Convergent validity
Convergent validity was evaluated by examining the correlations
of the I-TAQ domain scores with the scores of the ACCEPTEigenvalues
6.630 2.111 1.381 1.254
ed efﬁcacy)
ent treated your 0.911* 0.025 0.001 0.020
ting your condition? 1.026* 0.090* 0.107* 0.061*
-efﬁcacy)
ourself the injection 0.142 0.630* 0.006 0.237
jection treatment? 0.213* 0.676* 0.320* 0.233
ing yourself the 0.237* 0.413* 0.197* 0.366*
effects)
side effects of the 0.102 0.056 0.743* 0.005
ain you experienced 0.075 0.070 1.002* 0.058
convenience)
ay you had to store 0.141* 0.113 0.110* 0.823*
time it took to 0.086 0.133 0.007 0.918*
time it took to give 0.053 0.245* 0.092* 0.895*
umber of times you 0.025 0.178 0.030 0.824*
ourself the injection 0.182* 0.358* 0.103 0.734*
ction into your daily 0.173* 0.304* 0.082 0.803*
ing the injection 0.196* 0.124 0.173* 0.734*
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correlations (40.40) between the I-TAQ perceived efﬁcacy
domain and the ACCEPT efﬁcacy domain (r ¼ 0.51) as well as
between the I-TAQ acceptance of side effects domain and the
ACCEPT side effects of your medication domain (r ¼ 0.51). None of
the remaining two correlations hypothesized were observed, and
remaining correlations were all negligible (ro 0.20) in magnitude.Known-groups analysis
In an exploratory known-groups analysis, I-TAQ scores were
compared among different subgroups (Table 3). There was a
statistically signiﬁcant difference in mean I-TAQ perceived efﬁ-
cacy scores between patients with HeFH (n ¼ 51) and those
without HeFH (n ¼ 90). Patients with HeFH had signiﬁcantly
higher mean perceived efﬁcacy scores (75.7  24.4) than patients
without HeFH (65.7  29.4) (P ¼ 0.041).
It was expected that patients at very high risk of CV events
may have a higher acceptance score than patients at high risk
because of the increased perceived beneﬁt of treatment. There
were, however, no signiﬁcant differences in mean scores betweenFig. 2 – Final conceptual framework for the I-TAQ. I-TApatients with high (85.1  10.0) and very high (87.5 11.5) CV risk
for any of the I-TAQ domains or the total score (P ¼ 0.198).
There was a statistically signiﬁcant difference in mean I-TAQ
perceived efﬁcacy scores between patients using a preﬁlled pen
(65.8  28.2) and those using a preﬁlled syringe (80.9  23.0) (P o
0.005). The difference in mean scores for the other domains and
total score were not statistically signiﬁcant (P ¼ 0.073–0.697).
It was expected that patients who had higher overall accept-
ance on the PGI-A would also have higher acceptance scores on
the I-TAQ. For all domains and the total score, higher I-TAQ
scores were observed for those patients with higher PGI-A scores,
with monotonic increases in scores across the three groups
(Table 3). Differences in mean scores for all groups across each
domain and total score were statistically signiﬁcant (P o 0.001).Discussion
Health care providers and other health care decision makers can
have concerns regarding the acceptability of subcutaneous injec-
tions for the treatment of chronic and asymptomatic conditionsQ, Injection-Treatment Acceptance Questionnaire.
Fig. 3 – CFA four-factor structure. Note. Items with standardized coefﬁcientso0.30 would be ﬂagged as candidates for possible
deletion. Items 5, 6, and 7 were excluded from this analysis because of low response numbers. Items 3 and 11 were
dichotomous gateway items and were also excluded from this analysis. CFA, conﬁrmatory factor analysis.
V A L U E I N H E A L T H ] ( 2 0 1 6 ) ] ] ] – ] ] ]8such as elevated LDL-C levels, especially in situations in which
oral therapies are common and well established. As such, a valid
and reliable measure of treatment acceptance for evaluating
treatments is needed to quantify patient acceptance. To address
this need, the I-TAQ was developed using methods in line with
the present best practice guidance for the development and
validation of PRO instruments [16–18]. Speciﬁcally, appropriate,
in-depth qualitative work and rigorous psychometric methods
were used to ensure the content validity of the I-TAQ.
The results presented here provide encouraging initial evi-
dence of acceptable measurement properties for the I-TAQ in this
population of high CV risk patients being treated with a subcuta-
neous injection for lowering LDL-C levels. Item response distri-
butions were skewed toward the upper end of the scale
(indicating high acceptance), but it is likely that this is due to
the sample having high acceptance of their treatment and the
mode of administration rather than being indicative of a problem
with the instrument. This interpretation is consistent with
previous qualitative ﬁndings in which most patients (n ¼ 28;
97%) reported high acceptance [11] and it is perhaps not surpris-
ing given that all participants provided consent to participate in a
clinical trial of a subcutaneous treatment. High interitem corre-
lations were identiﬁed between a number of item-pairs, including
items 14 and 15, assessing the time required to prepare the
injection and the time required to take the injection. Such high
item correlations are, however, difﬁcult to interpret in the context
of the skewed distributions. Moreover, consideration of the
qualitative research and the item content suggests that all are
conceptually distinct and so all were retained pending further
study. Examining Cronbach α for each domain with each item
removed in turn found that the removal of only two items would
result in a very minor increase in internal reliability—in all other
cases Cronbach α decreased. This provides evidence that the
items within domain scores are all closely related, are eachcontributing to the domain score, and that their removal did
not improve the reliability of the domain score.
CFA, EFA, and multitrait analysis were conducted to examine
the appropriateness of the a priori conceptual framework. Both
CFA and EFA results supported the hypothesized ﬁve-domain
structure, with high factor loadings and minimal cross loading.
Nevertheless, because the overall acceptance domain correlated
with all domains, it was removed from the calculation of the total
score. None of the psychometric or previous qualitative ﬁndings
supported the deletion of any items and therefore all items were
retained. Psychometric evaluation of the resulting I-TAQ scoring
algorithm supported the construct validity of the instrument.
Factor analysis results supported the scoring algorithm, and
multitrait analysis showed that almost all items correlated highly
with the domains in which they were included (and more highly
than with any other domain) and all domains showed high
internal consistency.
Results for concurrent or convergent validity were mixed, and
these are again difﬁcult to interpret in the context of the skewed
response distributions. For concurrent or convergent validity,
there were some moderate correlations with the ACCEPT
domains, supporting the convergent validity of the I-TAQ. Other
domains expected to correlate did not (i.e., I-TAQ injection
convenience and ACCEPT medication inconvenience and regi-
men constraints; I-TAQ injection self-efﬁcacy and ACCEPT effec-
tiveness; I-TAQ overall acceptance and ACCEPT general
acceptance). Nevertheless, this perhaps reﬂects the fact that the
ACCEPT is a generic measure of treatment acceptance (asking
about medicines in general) and is not speciﬁc to injections,
whereas the I-TAQ questions focus speciﬁcally on acceptance
toward a subcutaneous mode of administration.
Overall, patients taking alirocumab via subcutaneous injec-
tion had high acceptance of the treatment. For example, 92.1% of
patients found self-injection with the preﬁlled pen or preﬁlled
Table 3 – Multitrait, internal consistency and known-groups analyses.
Perceived efﬁcacy Acceptance of side
effects
Acceptance of
self-efﬁcacy
Acceptance of injection
convenience
Overall acceptance Total score
Multitrait analysis
Item convergent
validity: item-
domain score
correlations range,
corrected for
overlap*
0.89 0.25–0.31 0.47–0.67 0.56–0.82 0.54–0.65 –
Percentage of items
that met the
criterion for item
discriminant
validity†
100% 60% 100% 100% 100% –
Internal consistency
Cronbach α – 0.75 0.72 0.88 0.73 0.75
Known-groups analysis
n Mean  SD P value n Mean  SD P value n Mean  SD P value n Mean  SD P value n Mean  SD P value n Mean  SD P value
PGI-A
response groups:
o0.001 o0.001 o0.001 o0.001 o0.001
1–7 16 50.0  23.3 18 88.6  16.9 18 82.4  20.8 18 77.8  17.9 18 71.3  13.2 o0.001 16 75.4  12.7
8 and 9 53 64.2  23.4 54 96.8  6.6 55 88.6  13.5 55 81.8  12.2 55 82.7  12.2 52 82.8  8.3
10 72 77.4  29.4 77 98.6  4.3 78 95.2  9.5 78 91.5  11.7 78 91.5  12.3 71 90.7  10.1
HeFH 51 75.7  24.4 0.041 50 97.1  6.1 0.731 51 90.2  14.8 0.482 51 85.3  14.8 0.521 51 86.6  14.4 0.649 50 87.1  10.6 0.389
Non-HeFH 90 65.7  29.4 99 96.6  9.2 100 91.8  12.8 100 86.8  13.3 100 85.5  13.8 89 85.4  11.4
Auto-injector 102 65.8  28.2 0.005 112 96.2  9.0 0.073 112 92.1  12.7 0.211 112 87.0  13.7 0.211 112 86.0  13.4 0.697 102 85.3  10.9 0.240
Preﬁlled syringe 36 80.9  23.0 34 98.4  5.0 36 88.0  15.6 36 83.6  14.3 36 86.0  16.3 34 87.9  11.6
High CV risk 67 66.0  30.0 0.107 66 97.3  6.1 0.384 68 91.3  11.5 0.691 68 85.7  13.7 0.488 68 85.5  12.8 0.514 65 85.1  10.0 0.198
Very high CV risk 62 74.0  25.1 70 96.1  10.1 70 92.1  13.3 70 87.3  13.7 70 87.0  13.9 62 87.5  11.5
* Item-domain correlations (corrected for overlap) 40.40 are considered evidence of adequate item convergent validity.
† Discriminant validity met when an item correlated higher with its own domain than with any other domain.
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V A L U E I N H E A L T H ] ( 2 0 1 6 ) ] ] ] – ] ] ]10syringe to be acceptable or very acceptable, with 94.7% of patients
feeling conﬁdent in their ability to self-inject alirocumab.
It is noted that the analyses of known-groups validity were
exploratory with hypotheses having to be made without previous
data to guide how acceptance might vary among patient subgroups.
Minimal differences in acceptance scores were observed between the
groups, with only the perceived efﬁcacy domain demonstrating
signiﬁcant differences in scores for all but one of the analyses. The
exception was the comparison of I-TAQ scores among groups deﬁned
by PGI-A responses in which differences in mean scores for all
domains and the total score were statistically signiﬁcant (P o 0.001).
It must be acknowledged that it would have been preferable to use a
validated measure of overall acceptance to deﬁne groups rather than
the PGI-A, which was developed speciﬁcally for this study (i.e., it
could be regarded as slightly circular that validity of the newly
developed measure was evaluated against a global item that has not
itself been validated). Nevertheless, because no such measure was
identiﬁed, the PGI-A was developed to facilitate a known-groups
comparison, and we suggest that the use of global assessments
without evidence of validity in psychometric studies is not uncom-
mon. A further limitation is the fact that the groupings of the PGI-A
were skewed to reﬂect the skewed data and ensure there was a
sufﬁcient number of patients in each group. In a less skewed data
set, the grouping of the PGI-A would be more evenly distributed.
Between patients with HeFH and those without HeFH, no differences
in acceptance of side effects, perceived self-efﬁcacy, injection con-
venience, and overall acceptance score were noted, although patients
with HeFH reported higher perceived efﬁcacy scores. Likewise, in a
comparison of preﬁlled pen and preﬁlled syringe, the only signiﬁcant
difference was in the perceived efﬁcacy domain. This was encourag-
ing given it was hypothesized that patients using the preﬁlled syringe
would have lower acceptability scores compared with those using
the preﬁlled pen [19].Most of the patients using a preﬁlled syringe (n
¼ 32 of 36; 88.9%), however, were diagnosed with HeFH, and so it is
possible that this ﬁnding was confounded by the presence of HeFH.
Study Limitations and Further Research
In addition to the limitations noted earlier regarding the PGI-A,
several other limitations should be considered when interpreting
the results of this study. Some of the patients were enrolled in open-
labeled trials and therefore had been receiving alirocumab for a long
time before taking part in this study. They reported high treatment
acceptance in these trials. Adaptation to treatment may have
occurred, but this would also be expected in routine clinical care.
As noted previously, this resulted in a lack of variation in response
distributions, with responses skewed toward the positive end of the
scale, which should be considered when interpreting all results.
Furthermore, very few patients reported side effects, therefore
resulting in only a small sample responding to these items, which
limited the assessment of the side effects domain. Assessing
psychometric properties of the measure in a population in which
greater distributions of responses are expected and in populations
more recently exposed to treatment that may also have side effects
is recommended to further evaluate the psychometric properties of
the I-TAQ. Given the multidimensional nature of the I-TAQ, a
modern psychometric model such as Rasch or item response theory
was not considered appropriate during this study. Nevertheless, the
use of such methods to evaluate the dimensionality within the
domains of the I-TAQ could be considered in the future.
The qualitative results supported an a priori conceptual frame-
work that provided rationale to conduct CFA. Because of the
skewed data, EFA was also conducted to further explore whether
other item-scale structures should be considered. It would have
been preferable to conduct the CFA and EFA in different samples,
and indeed to then perform the evaluation of the instrument
properties in a separate sample. This was not possible with thedata presently available, but it is recommended that further
evaluation be performed in future studies.
The I-TAQ has been developed as a measure of treatment
acceptance related to taking an injectable treatment in a clinical
trial. Although the I-TAQmeasures concepts that would potentially
be relevant to other patient populations in which treatment is self-
administered via injection, further content validity and psycho-
metric evaluation in other patient populations would be required
to support wider use. It is also acknowledged that the I-TAQ was
developed for use in clinical trials and there are limitations in
generalizing data collected to real-world experience of injection
treatments. Again, further evaluation in a real-world population is
necessary to conﬁrm the instrument’s applicability in that context
of use. Similarly, participants were recruited from studies that were
close to completion; therefore, it was not possible to administer the
instrument at two time points to support the evaluation of test-
retest reliability. Furthermore, no insights into the responsiveness
of the measure to alternative strategies (preﬁlled syringes vs.
preﬁlled pens) or educational interventions were explored and so
should be assessed in future studies. Finally, the measure has been
evaluated only in US-English–speaking populations; it is recom-
mended that further validation be performed in other languages
and cultures to conﬁrm cross-cultural validity of the instrument. In
summary, although the present results are encouraging, there is
much further work that could be performed.Conclusions
These ﬁndings provide initial evidence that the I-TAQ has accept-
able psychometric properties in patients with high CV risk treated
with subcutaneous alirocumab. Results provide evidence of accept-
able reliability and construct validity as a measure of patient-
reported treatment acceptance in this speciﬁc population, with the
potential to provide a valuable PRO for evaluating patients’ accept-
ance of therapies requiring subcutaneous injection.Acknowledgments
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